Document Detail


Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
MedLine Citation:
PMID:  1699704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated the safety and efficacy of Fluosol DA-20% (FDA) as a blood substitute in the treatment of severe anemia. Thirty-six patients received either FDA (n = 21) or crystalloid/hydroxyethyl starch (CHS) (n = 15) as part of a randomized, controlled trial. Ten patients received FDA as part of a humanitarian protocol. All were Jehovah's Witnesses who refused transfusion, had bled recently, and had average Hgb levels of 4.3 g/dl. After pulmonary artery catheter insertion, each patient was infused with CHS to attain a pulmonary artery wedge pressure (WP) of 10 to 18 mm Hg. FDA was given as a one-time dose of 30 ml/kg. Data were collected at baseline, 12, 24, and 48 h. None of the patients with negative reactions to a 0.5-ml test dose of FDA had adverse reactions to the subsequent infusion. The plasma or dissolved component of oxygen content was significantly higher in the FDA group at 12 h (FDA group 1.58 +/- 0.47 ml/dl, control group 1.01 +/- 0.31 ml/dl, p less than .02, t-test). Nineteen patients died: 12 (37.5%) FDA, seven (46.6%) control. The difference was not significant. We conclude the following: a) FDA can be given safely to severely anemic patients in doses of 30 ml/kg; b) FDA significantly increased the dissolved component of oxygen content after 12 h but the effect did not persist; c) severely anemic patients can survive without transfusion although mortality is high. In this study, inability of FDA to sustain increased oxygen content was due in part to the rapid elimination of FDA and also to the limited amount given.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
R K Spence; S McCoy; J Costabile; E D Norcross; M J Pello; J B Alexander; C Wisdom; R C Camishion
Related Documents :
11550164 - Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the respo...
2776794 - An unusual scintigraphic pattern in sickle cell patients.
20404424 - Hematuria in patients with beta-thalassemia major.
12421214 - Polymerized human hb use in acute chest syndrome: a case report.
7757274 - Current status of the prospective, randomized trials of symptomatic carotid bifurcation...
18332974 - The sphincter of oddi and acute pancreatitis - revisited.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Critical care medicine     Volume:  18     ISSN:  0090-3493     ISO Abbreviation:  Crit. Care Med.     Publication Date:  1990 Nov 
Date Detail:
Created Date:  1990-12-10     Completed Date:  1990-12-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1227-30     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Cooper Hospital/University Medical Center, Robert Wood Johnson Medical School, Camden 08103.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anemia / therapy*
Blood Substitutes / therapeutic use*
Christianity
Drug Combinations
Female
Fluorocarbons / adverse effects,  therapeutic use*
Hetastarch / therapeutic use
Humans
Male
Middle Aged
Oxygen / blood
Prospective Studies
Chemical
Reg. No./Substance:
0/Blood Substitutes; 0/Drug Combinations; 0/Fluorocarbons; 75216-20-5/Fluosol-DA; 7782-44-7/Oxygen; 9005-27-0/Hetastarch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Application of protein A-rosette assay for screening of monoclonal antibodies to human complement re...
Next Document:  Ringer's acetate and dextran-70 with or without hypertonic saline in endotoxin-induced shock in pigs...